Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,154 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Infection Clear all
Recruiting Phase 2 Interventional

The Safety and Efficacy of Roflumilast Foam in HS

NCT07263230
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Roflumilast 0.3% topical foam
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 21, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With a Mild Infection of a Foot Ulcer

NCT00593567
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
gentamicin-collagen sponge, Levofloxacin
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pasadena, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 21, 2026, 11:23 PM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

NCT07049575
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ruxolitinib Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Fountain Valley, California • Northridge, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 11:23 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis

NCT00680134
View directory record Official record
Conditions
Onychomycosis
Interventions
AN2690
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Albuquerque, New Mexico + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 21, 2026, 11:23 PM EDT
Recruiting Phase 4 Interventional

Skin Preparation for Elective Foot and Ankle Surgery

NCT05401292
View directory record Official record
Conditions
Microbial Colonization, Foot and Ankle Disorders
Interventions
Hibiclens, Isopropyl Alcohol 70% Topical Application Solution
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 21, 2026, 11:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cumulative Irritation Test

NCT00781664
View directory record Official record
Conditions
Tinea Pedis
Interventions
AN2718, AN2718, Sodium Lauryl Sulfate
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 21, 2026, 11:23 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections

NCT00711802
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
Daptomycin, Standard of Care (SOC)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
1 Year to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
22
States / cities
Birmingham, Alabama • Oakland, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 21, 2026, 11:23 PM EDT
Completed Phase 1 Interventional

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

NCT02635672
View directory record Official record
Conditions
Neoplasms
Interventions
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 21, 2026, 11:23 PM EDT
Completed No phase listed Observational

Oral Bacteria and Allergic Disease in Children

NCT00438646
View directory record Official record
Conditions
Asthma, Rhinitis, Eczema, Respiratory Sounds, Hypersensitivity
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
6 Years to 11 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2009 · Synced Oct 21, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

2% Chlorhexidine Gluconate Skin Cloths to Prevent SSI in Spine Surgery Patients

NCT02490631
View directory record Official record
Conditions
Surgical Site Infections, Post Operative Complication
Interventions
2% chlorhexidine gluconate cloths
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
19 Years to 90 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 21, 2026, 11:23 PM EDT
Terminated Phase 2 Interventional Results available

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

NCT03075553
View directory record Official record
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma, HTLV-1 Infection, NK-Cell Lymphoma, Unclassifiable, Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Mycosis Fungoides, Refractory Adult T-Cell Leukemia/Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Mycosis Fungoides, Refractory Nasal Type Extranodal NK/T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Laboratory Biomarker Analysis, Nivolumab
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 21, 2026, 11:23 PM EDT
Completed No phase listed Observational

UT Southwestern Diabetic Foot Ulcers (DFU) and Osteomyelitis (DFO) Recruitment Database, Data and Tissue Repository

NCT02463500
View directory record Official record
Conditions
Diabetic Foot Ulcers, Osteomyelitis
Interventions
DFU
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 21, 2026, 11:23 PM EDT
Withdrawn No phase listed Observational

Study to Evaluate Bacterial Activity That Drives the Progression of Clinical Infection

NCT03854695
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 21, 2026, 11:23 PM EDT
Completed Phase 2 Interventional

Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors

NCT00004157
View directory record Official record
Conditions
Breast Cancer, Gestational Trophoblastic Tumor, Kidney Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions
filgrastim, recombinant interleukin-11
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 21, 2026, 11:23 PM EDT
Completed No phase listed Observational

Telavancin Observational Use Registry (TOUR)

NCT02288234
View directory record Official record
Conditions
Hospital Acquired Bacterial Pneumonia, Complicated Skin and Skin Structure Infections, Ventilator Associated Bacterial Pneumonia, Gram Positive Infection
Interventions
Vibativ
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
1,063 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 21, 2026, 11:23 PM EDT
Withdrawn Phase 2 Interventional

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

NCT04482933
View directory record Official record
Conditions
Neoplasms, High Grade Glioma, Glioblastoma Multiforme, Malignant Glioma of Brain, Anaplastic Astrocytoma of Brain, High-grade Glioma, Anaplastic Glioma, Giant Cell Glioblastoma
Interventions
Biological G207
Biological
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Aurora, Colorado • New York, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 21, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

NCT04430855
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 21, 2026, 11:23 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Sexual Health Empowerment for Women's Health

NCT03984695
View directory record Official record
Conditions
Cervical Cancer, Breast Cancer, Contraceptive Usage, Sexually Transmitted Diseases
Interventions
SHE-WOMEN
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 21, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies

NCT03973775
View directory record Official record
Conditions
Scabies
Interventions
Permethrin Cream 5%
Drug
Lead sponsor
Saptalis Pharmaceuticals LLC
Industry
Eligibility
2 Months to 65 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
5
States / cities
Dinuba, California • Long Beach, California • Pasadena, California + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 21, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of Bermekimab in Patients With Hidradenitis Suppurativa

NCT03512275
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bermekimab Monoclonal Antibody 400 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 21, 2026, 11:23 PM EDT
Completed Phase 1Phase 2 Interventional

Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis

NCT03018275
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Roseomonas mucosa
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 21, 2026, 11:23 PM EDT
Terminated No phase listed Observational

Sonographic Features of Cellulitis and Failure of Therapy

NCT01773499
View directory record Official record
Conditions
Cellulitis
Interventions
Not listed
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2015 · Synced Oct 21, 2026, 11:23 PM EDT
Completed Not applicable Interventional Results available

Physiologic Growth Hormone Effects in HIV Lipodystrophy

NCT00100698
View directory record Official record
Conditions
AIDS, HIV Infections
Interventions
recombinant human growth hormone, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2010 · Synced Oct 21, 2026, 11:23 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

NCT06956235
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Tulisokibart, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 11:23 PM EDT